2019-12-25
Emergex Vaccines Holding Ltd., a UK-based biotechnology company that uses cutting-edge technologies to develop novel synthetic vaccines against infectious diseases, recently succeeded in completing the preclinical testing of its lead vaccine candidate for Dengue Fever, developed based on Nature’s gene-chip peptides attached to a quantum cluster gold nanoparticle delivery system, being now ready...
